

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2007 (20.09.2007)

PCT

(10) International Publication Number
WO 2007/106022 A3

(51) International Patent Classification:

C07D 401/12 (2006.01) **A61P 29/00** (2006.01)
A61K 31/454 (2006.01) **C07C 323/40** (2006.01)
A61K 31/4545 (2006.01) **C07C 323/41** (2006.01)
A61P 11/06 (2006.01) **C07D 233/76** (2006.01)
A61P 11/08 (2006.01)

WELLS, Andrew [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE 11 5RH (GB).

(74) **Agent: ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2007/000256

(22) International Filing Date: 15 March 2007 (15.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/782,979 16 March 2006 (16.03.2006) US

(71) **Applicant (for all designated States except US): ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): BARNWELL, Neil** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE 11 5RH (GB). **BRIGGNER, Lars-Erik** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **COLE, Andrea** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE 11 5RH (GB). **ERIKSSON, Anders** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **PERKINS, Jacob** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE 11 5RH (GB). **VAZ, Luis-Manuel** [FR/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE 11 5RH (GB).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) **Date of publication of the international search report:**

1 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYLMETHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF.

(57) **Abstract:** Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.

WO 2007/106022 A3